Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about a class action lawsuit related to the company's IPO, with a lead plaintiff deadline set for June 16, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding Zenas BioPharma's financial situation, specifically overstating the duration it could fund operations with existing cash and IPO proceeds [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4].
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm